INBX (Inhibrx Biosciences) Net earnings per share growth this year

INBX (Inhibrx Corp) - company brandmark

Inhibrx Biosciences (INBX) relies on external contractors for manufacturing and testing to maintain workforce flexibility. The YoY net income per share trend on GURU.Markets shows a figure at -5.90, which offsets market noise. Management is skillfully investing cash following the deal with Sanofi, although the lack of stable revenue leaves the company dependent on new funding rounds.

Earnings per share growth in current year: Inhibrx (INBX) for 07/04/2022 - 11/16/2026

Financial and market metric breakdowns for inhibrx.com (INBX)

Summary company analysis:INBX Inhibrx Biosciences
Signature product of Inhibrx Biosciences

Investors are assessing the financial stability of Inhibrx Biosciences (INBX) through earnings per share (EPS) dynamics, which measure the annual growth rate of net income per share. By analyzing the percentage deviation of EPS from the previous year's level, one can determine how effectively the proprietary single-domain antibody technology converts into profit growth and ensures high business margins.

Key competitors

Earnings per share growth this year INCY|Earnings per share growth in current year Hutchison MediPharma|Net earnings per share growth this year nuvationbio.com (NUVB)|Earnings per share growth in current year Day One Biopharmaceuticals Inc (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year I-Mab Inc. IMAB|Fennec - Earnings per share growth in current year|HRTX - Earnings per share growth in current year|Earnings per share growth rate in current year Nuvectis Pharma, Inc.|CHRS: Earnings growth in current year|Net earnings per share change in current year Corbus Pharma CRBP|Net earnings per share growth this year CRDF|Earnings per share growth rate in current year BeyondSpring Inc. BYSI|Net earnings per share growth this year BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Earnings per share increase in current year|Citius Pharmaceuticals, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Earnings growth in current year|Earnings per share increase in current year CANF (Can-Fite BioPharma, Ltd.)|APRE: Earnings growth in current year|Earnings per share growth rate in current year Kazia (KZIA)|Earnings per share growth in current year silexion.com|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year Oncternal Therapeutics Inc|Portage Biotech (PRTG) - Earnings per share growth in current year